Germline mutations in ATM, CHEK2, and other known/potential breast cancer susceptibility genes among BRCA-negative Uruguayan patients with breast cancer.

Authors

Lucia Delgado

Lucia Beatriz Delgado

Hospital de Clínicas, Montevideo, Uruguay

Lucia Beatriz Delgado , Alfonso Cayota , Nora Artagaveytia , Noelia Silveyra Olivera , Sebastian Francisco Ximenez Gulaute , Gonzalo Manrique , Camila Simoes , Lucia Spangenberg , Hugo Naya , Julia Sanguinetti , Valentina Blanco , Natalia Camejo , Cecilia Castillo , Sandra Cataldi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Prevention, Risk Reduction, and Hereditary Cancer

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Germline Genetic Testing

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 10596)

DOI

10.1200/JCO.2022.40.16_suppl.10596

Abstract #

10596

Poster Bd #

471

Abstract Disclosures

Similar Posters

Poster

2017 ASCO Annual Meeting

Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.

Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.

First Author: Gregory Idos

Poster

2016 ASCO Annual Meeting

Next-generation sequencing in <i>BRCA1/2</i>-negative breast and ovarian cancer families.

Next-generation sequencing in BRCA1/2-negative breast and ovarian cancer families.

First Author: Jan Hauke

Poster

2017 ASCO Annual Meeting

Expanded yield of multiplex panel testing in fully accrued prospective trial.

Expanded yield of multiplex panel testing in fully accrued prospective trial.

First Author: Gregory Idos

Poster

2017 ASCO Annual Meeting

Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.

Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.

First Author: Allison W. Kurian